畢馬威預測香港今年新股集資額可重返全球前五位
畢馬威發表中國內地及香港新股市場回顧及展望,指出2023年全年全球首次公開發售(IPO)活動集資總額達到1,311億美元,涉及1,371宗上市,分別按年減少33%及10%。畢馬威中國新經濟市場及生命科學行業香港主管合夥人朱雅儀表示,去年香港IPO市場發展相對較慢,主要是受到全球市場不明朗,導致企業及投資者持觀望態度所致,憧憬本港資本市場基本面仍然穩健,加上近年港交所(00388.HK)進行一系列上市改革,包括引入特專科企18C章及GEM改革等,預期今年香港新股市道將迎來復甦,有望重返全球IPO集資額排名前五位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.